Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Supplementary Table 1. Sensitivity analyses without the missing category for the eligible SMR population compared to the TENAYA and LUCERNE populations.

Characteristics	SMR n = 13,265	TENAYA n = 334	p	LUCERNE n = 331	p
Time since AMD-diagnosis*			0.111		<0.001
≤ 1 month	9710 (82%)	248 (79%)		221 (70%)	
>1 month	2066 (18%)	66 (21%)		96 (30%)	
CNV location, n (%)			<0.001		<0.001
Subfoveal	7161 (71%)	201 (61%)		209 (65%)	
Juxtafoveal	2292 (23%)	88 (27%)		73 (23%)	
Extrafoveal	662 (7%)	41 (12%)		42 (13%)	
CNV lesion type, n (%)			<0.001		<0.001
Occult**	4139 (52%)	177 (55%)		171 (54%)	
Classic, including mixed membranes	2439 (31%)	133 (41%)		134 (42%)	
RAP	1319 (17%)	14 (4%)		14 (4%)	

AMD, age-related macular degeneration; CNV, choroidal neovascularization; PCV, polypoidal choroidal vasculopathy; SMR, The Swedish Macula Register; RAP, retinal angiomatous proliferation.

* 135 cases with a diagnosis time >365 days excluded from SMR.

** 418 PCV cases included.